Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema

Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema

Source: 
Pharmaforum
snippet: 

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it bought Kymab and its lead drug KY1005 for the skin disorder for $1.1 billion upfront. Now, it says the drug has delivered “exciting” results in a proof-of-concept trial.